Antithrombotic Strategies in Atrial Fibrillation. The XIX CONAREC Registry

Valentin Roel, Juan A. Moukarzel, Ezequiel Zaidel, Matias Galli, Walter Da Rosa, Rodolfo Leiva, Carolina Cicero, Jorge Thierer


Background: Atrial fibrillation (AF) represents the most common sustained arrhythmia. Treatment has evolved since thelast survey performed in our setting, with a marked trend towards the use anticoagulation therapy, and the development ofnew anticoagulation drugs. However, Argentina lacks updated data about antithrombotic therapy or the use of novel oralanticoagulants (NOAC).Objective: The aim of the study was to assess antithrombotic strategies in AF patients admitted for cardiovascular causes incenters with cardiology residency.Methods: Between September and November 2013, 927 patients with at least one episode of atrial fibrillation within the last12 months and hospitalized for cardiovascular causes in centers with cardiology residency were enrolled in the study.Results: Median values (interquartile range) of CHADS2 and CHA2DS2-VASc and HASBLED scores were: 2 (1-3), 3 (2-4) and1 (1-2), respectively. At admission, only 54% of patients with history of AF without contraindication and CHADS2≥1 (n=253)received anticoagulation therapy; 89% with dicoumarinic agents and only 26.5% in the therapeutic range. At discharge, anti

Full Text


  • There are currently no refbacks.

Licencia Creative Commons
The documents published in this journal are under the licencia Creative Commons Atribución-NoComercial-Compartir-Igual 2.5 Argentina.

Revista argentina de cardiología. ISSN en línea 1850-3748. Argentine journal of cardiology (English ed. Online ISSN 2314-2286) Sociedad Argentina de Cardiología. Azcuénaga 980 (C1115AAD),Ciudad Autónoma de Buenos Aires, República Argentina. Tel. (54 11) 4961-6027/8/9 Fax: 4961-6020